deltaDOT Bioprocess Technology Used for Regulatory Study
deltaDOT Ltd (London) can announce that its advanced bioprocess technology, the
HPCE-512, has been used in a regulatory study undertaken by the UK’s National Health Service
(NHS). Our client, Quality Control North West (Liverpool), is a division of the NHS which conducts
regulatory studies for the pharmaceutical industry. QCNW used deltaDOT’s HPCE-512 technology to
perform stability studies on a mAb biosimilar to allow it to be approved for human use.
For more information about the study please visit:
The data produced by deltaDOT’s HPCE-512 (relate to the stability of the mAb once formulated
into saline solution) can be seen in Figures 3,4 & 5 of this document.
More information about deltaDOT capabilities to analyse mAbs can be found on the deltaDOT